DTaP vaccine - Beijing Minhai BiotechnologyAlternative Names: Diphtheria tetanus-acellular pertussis vaccine - Beijing Minhai Biotechnology
Latest Information Update: 01 Sep 2015
At a glance
- Originator Beijing Minhai Biotechnology
- Developer Beijing Minhai Biotechnology; Jiangsu Provincial Center for Disease Control and Prevention
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Diphtheria; Pertussis; Tetanus